Nanoparticle-Mediated Interleukin-12 Cancer Gene Therapy


  • Crispin Dass
  • Somayeh Hallaj-Nezhadi
  • Farzaneh Lotfipour



Interleukin-12 (Il-12) is a heterodimeric cytokine which has been proved to possess antitumor effects in various animal models via stimulating the immune system. The main problem associated with Il-12 protein delivery is its instability as well as cytotoxicity subsequent to systemic administration in rodents and in human clinical trials. However, gene delivery can be used to deliver genes of interest to the tumor site. Hence, a large number of studies have been undertaken to deliver genes of interest to the tumor site through viral or non-viral vectors. Viral DNA delivery systems suffer from safety concern due to the toxicity of the viruses and strong immune response; while non-viral gene delivery systems proffer lower transfection efficiency. Nevertheless, nanometer-size complex of therapeutic DNA may demonstrate more efficient for administration of therapeutic genes to solid tumors compared to administration of naked plasmid DNA. Nanoparticle-based gene delivery systems might be more pertinent, due to the enhanced tissue penetrability, improved cellular uptake. Il-12 gene delivery has already been reported with different nanoparticles containing DNA. This article provides a review on the in vivo and in vitro studies using various nanoparticles, for delivery of the Il-12 genes to neoplastic cells. The future of these promising approaches lies in the development of better techniques for preparing il-12 gene delivery systems with complete efficiency of viral vectors in addition to the highest safety for cancer patients.


Download data is not yet available.




How to Cite

Dass, C., Hallaj-Nezhadi, S., & Lotfipour, F. (2010). Nanoparticle-Mediated Interleukin-12 Cancer Gene Therapy. Journal of Pharmacy & Pharmaceutical Sciences, 13(3), 472–485.



Review Articles